Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis: FATPs and apoptosis in NASH
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Hepatocyte apoptosis is a key event in non-alcoholic steatohepatitis (NASH). We studied the effect of obesity on free fatty acid (FFA) levels, fatty acid transport proteins (FATPs) and on extrinsic and intrinsic activation of apoptosis in the liver. METHODS: Liver biopsies were harvested from 52 morbidly obese patients [body mass index (BMI): 53.82+/-1.41; age: 45+/-10.50; 15 males/37 females] undergoing bariatric surgery, and were scored for NASH, evaluated for fibrosis, and investigated for intrahepatic expression of FATPs, death receptors and cytosolic apoptosis-related molecules. Findings were correlated with serum FFA levels and the degrees of intrahepatic (terminal dUTP nick end labelling) and systemic (M30) apoptosis. RESULTS: In patients' liver sections, FATPs as well as select parameters of extrinsic and intrinsic apoptosis were found to be upregulated (CD36/FAT: x 11.56; FATP-5: x 1.33; CD95/Fas: x 3.18; NOXA: x 2.79). These findings correlated with significantly elevated serum FFAs (control: 14.72+/-2.32 mg/dl vs. patients: 23.03+/-1.24 mg/dl) and M30 levels (control: 83.12+/-7.46 U/L vs. patients: 212.61+/-22.16 U/L). We found correlations between FATPs and apoptosis mediators as well as with histological criteria of NASH and fibrosis. CONCLUSIONS: Increased FFA and FATPs are associated with extrinsically and intrinsically induced apoptosis, liver damage and fibrosis in obese patients. Thus, FATPs may offer an interesting new approach to understand and potentially intervene NASH pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · cited 2×
“CD95 L/FasL or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) – to pro-apoptotic receptors such as CD95/Fas, DR4 or DR5 (21).”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 2×
“(i) in HepG2 hepatoma cells, FFAs promote the upregulation of CD95/ Fas in vitro (8); (ii) activation of caspases-3 and -7 in NASH liver samples correlates positively with the severity of disease and fibrosis as well as with results in HepG2 cells (6, 7, 9) and (iii) mitochondrial dysfunction upregulates the generatio…”
BackgroundSelf-citationNguyen, M. T. A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G., & Olefsky, J. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706762200 · Cited by 1,035
Susztak, K., Ciccone, E., McCue, P., Sharma, K., & Böttinger, E. P. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020045 · Cited by 214
Cited by
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
Self-citationNonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03003-w · Cited by 518
Wilson, C. G., Tran, J. L., Erion, D. M., Vera, N. B., Febbraio, M., & Weiss, E. J. (2016) · Endocrinology · doi:10.1210/en.2015-1866 · Cited by 463
Metadata
- Authors
- Bechmann, L. P., Gieseler, R. K., Sowa, J.-P., Kahraman, A., Erhard, J., Wedemeyer, I., Emons, B., Jochum, C., Feldkamp, T., Gerken, G., & Canbay, A.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2009-10-21
- Volume
- 30
- Issue
- 6
- Pages
- 850-859
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2135422400
- Cited by
- 120
- References
- 6
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis: FATPs and apoptosis in NASH. https://app.cochat.ai/papers/10.1111/j.1478-3231.2010.02248.x
- The paper
- Bechmann, L. P., Gieseler, R. K., Sowa, J.-P., Kahraman, A., Erhard, J., Wedemeyer, I., Emons, B., Jochum, C., Feldkamp, T., Gerken, G., & Canbay, A. (2009). Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis: FATPs and apoptosis in NASH. Liver International. https://doi.org/10.1111/j.1478-3231.2010.02248.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.